MAP2K1 and thyroid cancer: BRAFV600E-driven lung and thyroid cancers are also responsive to combined inhibition of BRAFV600E plus MEK1/2 using dabrafenib and trametinib, which are now FDA-approved standard of care for metastatic NCSLC and thyroid cancer patients [23,24].